Cardlytics Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Cardlytics de 60.2% y 8.5% respectivamente, mientras que el BPA crecerá en un 72.3% al año.

Información clave

60.2%

Tasa de crecimiento de los beneficios

73.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Media	11.9%
Tasa de crecimiento de los ingresos	8.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	20 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

May 31

Cardlytics, Inc. (NASDAQ:CDLX) Stock Rockets 105% But Many Are Still Ignoring The Company

Apr 17

Is Cardlytics, Inc. (NASDAQ:CDLX) Trading At A 38% Discount?

Mar 03

Is Cardlytics (NASDAQ:CDLX) A Risky Investment?

Jan 10

Is Cardlytics (NASDAQ:CDLX) Using Debt In A Risky Way?

Oct 12

Cardlytics: 6 Bear Cases To Consider

Oct 10

Cardlytics: Trying To Stem The Bleeding

Sep 27

BitPay adds Cardlytics-powered rewards program to its crypto prepaid card

Aug 10

Cardlytics slumps 16% after missing top and bottom line estimates

Aug 02

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:CDLX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	361	-59	-3	9	5
12/31/2024	319	-79	-42	-28	5
3/31/2024	312	-173	-22	-8	N/A
12/31/2023	309	-135	-13	0	N/A
9/30/2023	303	-412	-28	-16	N/A
6/30/2023	296	-382	-44	-32	N/A
3/31/2023	295	-485	-58	-44	N/A
12/31/2022	299	-465	-67	-54	N/A
9/30/2022	306	-99	-55	-41	N/A
6/30/2022	298	-150	-51	-37	N/A
3/31/2022	282	-71	-58	-46	N/A
12/31/2021	267	-129	-51	-39	N/A
9/30/2021	244	-124	-45	-32	N/A
6/30/2021	225	-94	-40	-27	N/A
3/31/2021	195	-67	-29	-17	N/A
12/31/2020	187	-55	-18	-8	N/A
9/30/2020	189	-45	-20	-9	N/A
6/30/2020	199	-38	-2	7	N/A
3/31/2020	220	-24	-1	10	N/A
12/31/2019	210	-17	0	11	N/A
9/30/2019	189	-32	-7	3	N/A
6/30/2019	167	-33	-20	-9	N/A
3/31/2019	154	-39	-29	-20	N/A
12/31/2018	151	-53	-26	-19	N/A
9/30/2018	142	-46	-25	-20	N/A
6/30/2018	139	-41	-32	-29	N/A
3/31/2018	136	-33	-18	-16	N/A
12/31/2017	130	-25	N/A	-22	N/A
9/30/2017	128	-28	N/A	-19	N/A
6/30/2017	127	-51	N/A	-16	N/A
3/31/2017	120	-77	N/A	-26	N/A
12/31/2016	113	-77	N/A	-32	N/A
12/31/2015	78	-42	N/A	-29	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CDLX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CDLX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CDLX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (8.5% al año) de CDLX crezcan más despacio que el mercado de US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 8.5% al año) de CDLX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CDLX se prevé que sea elevada dentro de 3 años.

Cardlytics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 33%

Price target decreased by 21% to US$14.00

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Consensus estimates of losses per share improve by 18%

Price target increased by 46% to US$17.00

No longer forecast to breakeven

Recent updates

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Consensus EPS estimates fall by 33%

Price target decreased by 21% to US$14.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Cardlytics, Inc. to Report Q1, 2024 Results on May 08, 2024

The Power Of Cardlytics' Data Partnerships Including Bank of America

Cardlytics, Inc., Annual General Meeting, May 23, 2024

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

CEO & Director notifies of intention to sell stock

Now 35% undervalued

Consensus estimates of losses per share improve by 18%

Cardlytics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Cardlytics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 46% to US$17.00

New major risk - Share price stability

No longer forecast to breakeven

Cardlytics, Inc. Provides Earnings Guidance for the First Quarter of 2024

CEO & Director notifies of intention to sell stock

Cardlytics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Cardlytics: Good Prospects But Macro Uncertain

High number of new directors

COO & GM of Bridg exercised options and sold US$443k worth of stock

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

CEO & Director notifies of intention to sell stock

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Kigo, LLC acquired HSP EPI Acquisition, LLC from Cardlytics, Inc. (NasdaqGM:CDLX).

CEO & Director exercised options and sold US$332k worth of stock

Consensus EPS estimates upgraded to US$1.32 loss, revenue downgraded

Cardlytics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Announces Resignation of Tony Weisman as Member of the Board and as Member of the Nominating and Corporate Governance Committee

Cardlytics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

Cardlytics, Inc. Appoints Alex Mishurov as Independent Director

CEO & Director recently sold US$2.9m worth of stock

Cardlytics, Inc. Announces Board Member Changes

Insider recently sold US$172k worth of stock

Consensus EPS estimates fall by 29%, revenue upgraded

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Insufficient new directors

Cardlytics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Cardlytics Appoints Alexis Desieno as New Chief Financial Officer

Cardlytics, Inc. Announces Board Changes

Cardlytics, Inc. Announces Board Changes

CEO & Director notifies of intention to sell stock

Does Cardlytics (NASDAQ:CDLX) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$1.87 loss, revenue downgraded

Price target increased by 9.8% to US$6.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2023

Cardlytics, Inc. (NASDAQ:CDLX) Stock Rockets 105% But Many Are Still Ignoring The Company

Price target increased by 8.9% to US$6.10

Full year 2022 earnings: EPS misses analyst expectations

Is Cardlytics, Inc. (NASDAQ:CDLX) Trading At A 38% Discount?

Price target decreased by 18% to US$7.40

Cardlytics, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Cardlytics Appoints Amit Gupta as Chief Operating Officer

Is Cardlytics (NASDAQ:CDLX) A Risky Investment?

Cardlytics, Inc. Announces Board Changes

Price target decreased to US$9.80

Co-Founder & Executive Chairman notifies of intention to sell stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind